Researchers from Tokyo University of Science (TUS) have found a simple, low-cost way to optimise the production of monoclonal antibodies (mAbs) and reduce manufacturing costs. Dr Kyohei Higashi, Associate Professor at TUS, along with a team of researchers, conducted a study to explore the effects of… Read More
As demand for mRNA continues to surge, two new facilities have been launched to boost production in Australia and the US. Work is underway at The University of Queensland’s (UQ) BASE facility which has become Australia’s leading provider of mRNA for research and pilot studies since… Read More
Fujifilm Corporation has announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will be operated by Fujifilm Irvine Scientific, a manufacturer of cell culture solutions for life science research, bioproduction, cell therapy… Read More
Stream this free webinar, hosted by DDW and supported by Catalent, Early phase support for plasmid DNA supply helps secure future manufacturing for advanced therapies. The webinar was presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production… Read More
Watch this free webinar, hosted by DDW and supported by Catalent, which will be presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based… Read More
One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material. Watch this free webinar – Early phase support for plasmid DNA supply… Read More
One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material. Watch this free webinar – Early phase support for plasmid DNA supply… Read More
This on-demand webinar, hosted by DDW and supported by Catalent, is presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene… Read More
One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material. Watch this on-demand webinar – Early phase support for plasmid DNA supply… Read More
Astrea Bioseparations has launched its Nereus LentiHERO lentiviral vector (LVV) purification technology commercially. Incorporating AstreAdept, the company’s proprietary nanofiber material, this solution has been created to address the challenges associated with purifying the large and fragile products used in cell and gene therapy. AstreAdept is a proprietary bioseparations material that… Read More
Listen to this article on the DDW Podcast: Grant Cameron, Director at Clydeworth Consulting, examines the benefits of process intensification and highlights the steps which will improve process productivity, reduce environmental impact and decrease the cost of therapy manufacture while maintaining product quality. The move to… Read More
Sartorius was named the award winner for “Overall Best Bioprocessing Supplier” at the Europe Bioprocessing Excellence Awards 2021. According to award organizer IMAPAC, the awards seek to recognise exceptional bioprocessing experts, organisations, and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality across Europe and the… Read More
PerkinElmer has entered into an agreement to acquire BioLegend, provider of life science antibodies and reagents, for approximately US$5.25 billion. The transaction will be the largest in PerkinElmer’s history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing… Read More
Thermo Fisher Scientific has launched the Thermo Scientific Herasafe 2025 BSC, for the safe sample handling needs of life science applications. It is a Class II Biological Safety Cabinet (BSC) designed to meet the sample and user protection requirements of bioprocessing, clinical diagnostic and biopharmaceutical laboratories. According to Thermo Fisher… Read More
Six bioprocessing innovators have successfully completed the inaugural Testa Challenge 2020. Held over an intensive week in the Testa Center located at Cytiva´s Uppsala site, a biomanufacturing scale-up facility, the Testa Challenge aims to allow start-ups, research groups and companies from around the world to run and validate their innovative… Read More
CPhI Annual Report 2020 highlights cell and gene therapy capacity shortages in the USA and 10+ mAb approvals in China. Continuous Bioprocessing growing quickly, but from a low base, with virtually all manufacturers now using at least some single use technologies. CPhI Annual Report – launched ahead of the… Read More
